Long Term Vitamin D Therapy in HCV Treated Patients

Effect of Long-term Vitamin D Therapy on IL-6, Visfatin and Hyaluronic Acid in Hepatitis C Virus Patients' Assessment

Status

Terminated

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01997203

Acronym

VD-HCV

Enrollment

100

Registered

2013-11-28

Start date

2012-04-30

Completion date

2013-04-30

Last updated

2013-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis C

Keywords

hepatitis C infection, vitamin D

Brief summary

Treatment of hepatitis C virus (HCV) infection was carried out using pegylated interferon (PEG-IFN), ribavirin (RBV) and vitamin D (vit D) for 48 weeks in HCV genotypes 4a subjects. The purpose of this study is to determine the effect of vitamin D on liver affection in such patients.

Detailed description

Fifty patients study group administered vit D were compared with 50 patients control group without vit D. The results showed a significant elevation in vit D levels during the time period, and significant reduction on HCV RNA from the 12th wk to reach zero level in 24th wk. Interleukin 6 (IL-6), visfatin and hyaluronic acid levels were reduced significantly to reach normal values. These concentrations reduction by the effect of vit D on HCV indicated the reduction in inflammation, infection and liver cirrhosis and nearly amelioration HCV.

Interventions

DRUGVitamin D

vitamin D was given to 50 patients (HCV under treatment)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Inclusion criteria

* Chronic HCV infection (positive HCV Ab more than 6 months) * Treated with pegylated interferon and ribavirin

Exclusion criteria

* Coinfection with Hepatitis B or Hepatitis D or Human Immunodeficiency Virus * Previous non response to antiviral therapy. * Other causes of chronic liver diseases as schistosomiasis, Wilson disease and alcoholic liver disease.

Design outcomes

Primary

Measure	Time frame
composite measures of Vitamin D, IL-6, Visfatin and Hyaluronic acid in Hepatitis C Virus Patients under antiviral therapy	48 weeks

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026